<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228552</url>
  </required_header>
  <id_info>
    <org_study_id>79,629</org_study_id>
    <nct_id>NCT01228552</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine</brief_title>
  <official_title>A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Behar, Caren, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Behar, Caren, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of intra-oral topical
      ketoprofen for the treatment of acute migraine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief (defined as at least 2 graded reduction in a 5-grade scale) at 120 minutes post-treatment</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain free status at 30, 60, 120, and 240 minutes post-treatment based on headache severities reported in patient's journals</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief at 30, 60, and 240 minutes post-treatment based on headache severities reported in patient's journals</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of Photophobia at 30, 60, 120, and 240 minutes post-treatment</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of Phonophobia at 30, 60, 120, and 240 minutes post-treatment</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of Nausea at 30, 60, 120 and 240 minutes post-treatment</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of Vomiting 30, 60, 120 and 240 minutes post-treatment</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Rescue Medication between the time of dosing to 240 minutes</measure>
    <time_frame>Within 240 minutes post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Migraine Disorders</condition>
  <condition>Migraine Headache</condition>
  <condition>Migraine</condition>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Topical, intra-oral ketoprofen gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical, intra-oral ketoprofen gel</intervention_name>
    <description>Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.</description>
    <arm_group_label>Topical, intra-oral ketoprofen gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.</description>
    <arm_group_label>Placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of Migraine as per IHS with aura

          -  Established diagnosis of Migraine as per IHS without aura

          -  At least 2 migraines per month

          -  At least 18 years of age

        Exclusion Criteria:

          -  Pregnancy or Lactation

          -  Other Headache Conditions including basilar, hemiplegic, or ophthalmoplegic migraines

          -  Chronic Daily Headache

          -  Allergy or Sensitivity to NSAIDs

          -  Other Severe Medical Conditions including GI bleeding, blood dyscrasias,
             thrombocytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caren Behar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caren Behar, MD</last_name>
    <phone>914-584-2413</phone>
    <email>ardavsa@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Caren Behar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>June 4, 2011</last_update_submitted>
  <last_update_submitted_qc>June 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Behar, Caren M.D.</name_title>
    <organization>New York Medical College</organization>
  </responsible_party>
  <keyword>Acute Migraine Treatment</keyword>
  <keyword>Migraine Treatment</keyword>
  <keyword>Migraine</keyword>
  <keyword>Headache</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

